New: Biosimilars strategies introduced.
Close
Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
December 14, 2022 - Fresenius Kabi announced the FDA approval of Idacio (adalimumab-aacf), a biosimilar to AbbVie’s Humira® (adalimumab).
Download PDF
Return to publications
